The MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick...
Read moreWe summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...
Read moreWe've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...
Read moreWe outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreAmong the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read moreThe Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreNICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...
Read more